215 related articles for article (PubMed ID: 8966141)
1. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
Matuszkiewicz-Rowińska J; Niemczyk S; Pacocha E; Puka J; Switalski M; Bogdańska-Straszyńska B; Ostrowski K
Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol].
Switalski M; Kuriga M; Wańkowicz Z
Pol Arch Med Wewn; 1997 Oct; 98(10):358-65. PubMed ID: 9557090
[TBL] [Abstract][Full Text] [Related]
4. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
6. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
7. Alphacalcidol oral pulses are effective in secondary hyperparathyroidism prior to dialysis.
Koskimies O; Ala-Houhala M
Clin Nephrol; 1996 Jul; 46(1):70-1. PubMed ID: 8832157
[TBL] [Abstract][Full Text] [Related]
8. [Oral pulsatile therapy with active vitamin D3 metabolites--an efficient method of parathyroid hormone synthesis suppression in uremic patients with severe hyperparathyroidism. A pilot study].
Matuszkiewicz-Rowińska J; Niemczyk S; Bogdańska-Straszyńska B; Ostrowski K
Pol Arch Med Wewn; 1993 Feb; 89(2):95-101. PubMed ID: 8502602
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
[TBL] [Abstract][Full Text] [Related]
10. [Combined therapy with calcitonin and high doses of active vitamin D3 metabolites in uremic hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Puka J; Sawicki A; Switalski M; Tałałaj M; Pacocha E; Marusza W; Ostrowski K
Pol Arch Med Wewn; 1996 Jul; 96(1):23-31. PubMed ID: 8966142
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Storm T; Olgaard K
Nephron; 1989; 53(3):194-200. PubMed ID: 2797340
[TBL] [Abstract][Full Text] [Related]
12. The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
Tsukamoto Y; Nomura M; Takahashi Y; Takagi Y; Yoshida A; Nagaoka T; Togashi K; Kikawada R; Marumo F
Nephron; 1991; 57(1):23-8. PubMed ID: 2046811
[TBL] [Abstract][Full Text] [Related]
13. Long-term suppression of secondary hyperparathyroidism by intravenous 1 alpha-hydroxyvitamin D3 in patients on chronic hemodialysis.
Brandi L; Daugaard H; Tvedegaard E; Nielsen PK; Egsmose C; Storm T; Olgaard K
Am J Nephrol; 1992; 12(5):311-8. PubMed ID: 1488999
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
Rapoport J; Mostoslavski M; Ben-David A; Knecht A; Blau A; Arad J; Zlotnik M; Chaimovitz C
Nephron; 1996; 72(2):150-4. PubMed ID: 8684518
[TBL] [Abstract][Full Text] [Related]
15. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
[TBL] [Abstract][Full Text] [Related]
16. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
Perez-Mijares R; Gomez-Fernandez P; Almaraz-Jimenez M; Ramos-Diaz M; Rivero-Bohorquez J
Am J Nephrol; 1993; 13(2):149-54. PubMed ID: 8342582
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease.
Tarrass F; Yazidi A; Sif H; Zamd M; Benghanem MG; Ramdani B
Clin Nephrol; 2006 Jun; 65(6):415-8. PubMed ID: 16792136
[TBL] [Abstract][Full Text] [Related]
18. [Effect of pulse therapy using 1 alpha(OH)D on secondary hyperparathyroidism in patients on maintenance hemodialysis].
Yoshida K; Hirayama A; Tanaka N; Yasukawa M; Saka M; Kaneko Y; Maruyama Y; Motomiya Y; Ozono S; Hirao Y
Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1117-23. PubMed ID: 2287104
[TBL] [Abstract][Full Text] [Related]
19. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
Alghareeb A; Sabry A; Bawadekji H; Alsaran K
Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
[TBL] [Abstract][Full Text] [Related]
20. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
